Orexigen Therapeutics Inc (NASDAQ:OREX)

Data as of Oct 22
 -0.19 / -4.21%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of pharmaceutical product candidates for the treatment of obesity. Its product candidate, NB32, is an investigational medicine for weight loss and the maintenance of weight loss; and Empatic used for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Contact Information

Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
La Jolla California 92037
P:(858) 875-8600
Investor Relations:
(858) 875-8629



Mutual fund holders42.45%
Other institutional31.17%
Individual stakeholders19.77%

Top Executives

Michael A. NarachiPresident, Chief Executive Officer & Director
Joseph P. HaganCFO, Treasurer & Chief Business Officer
Heather D. TurnerSecretary, Senior Vice President & General Counsel
Preston S. KlassenSenior Vice President & Head-Global Development
Dawn ViveashSenior VP & Head-Global Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.